Screener
Cytokinetics CYTK Development And Commercial Milestones — Maximum Milestone Additional Amount Receivable
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept cytk:MaximumMilestoneAdditionalAmountReceivable.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
The Company earned €10.0 million in the first quarter of 2026 and remains eligible to receive up to an additional €70.0 million upon achievement of development and commercial milestones. The Company is also eligible to receive up to an additional €490.0 million in commercial milestone payments upon the achievement of certain sales milestones, and tiered royalties on net sales of aficamten in Japan.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's development and commercial milestones — maximum milestone additional amount receivable?
- Cytokinetics (CYTK) reported development and commercial milestones — maximum milestone additional amount receivable of $70M in Q2 2026.
- What does development and commercial milestones — maximum milestone additional amount receivable mean?
- This metric quantifies the total potential future payments that the company is eligible to receive upon the successful achievement of remaining clinical, regulatory, or commercial milestones under existing partnership agreements. It serves as a forward-looking indicator of the value embedded in the company's collaboration portfolio and the potential non-dilutive capital available from partners. Tracking this figure helps investors assess the upside potential of the company's pipeline development progress.
Ask your AI about Cytokinetics's development and commercial milestones — maximum milestone additional amount receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude